NCT00669045已完成不适用
A Phase IV, Prospective, Observational Study of TNKase in Patients Enrolled in the National Registry of Myocardial Infarction 4 and 5 (POST)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 253,668
研究概览
简要总结
The POST study comprised patients whose data were entered into the NRMI 4 and 5 databases. NRMI is a prospective, observational study of patients presenting with AMI in the United States. NRMI was launched in 1990 and to date has enrolled more than 2.5 million AMI patients. More than 1,700 hospitals have participated in NRMI during the last 16 years. The NRMI 4 and 5 substudies were sponsored by Genentech and collected data on approximately 160,000 AMI patients (both ST elevation and non-ST-elevation MI) hospitalized in the United States each year. This corresponds to approximately 18% of the AMI patients in the United States.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Presence of LBBB or ST-segment elevation (new or of unknown duration)
- •ICD-9-CM discharge code of 410.X1
- •Treatment with one of the following regimens: TNKase; Other thrombolytic regimens; No initial reperfusion
排除标准
- •Patients who were transferred out of the facility
- •Patients with pending data clarification forms on fields related to study variables
研究者
相似试验
招募中
Unknown
A long term safety follow-up study for subjects who received 3 doses of Pneumococcal Vaccine.CTRI/2024/07/071627Biological E.Limited
终止
不适用
Controlled High Risk AVONEX® Multiple Sclerosis Prevention Study In Ongoing Neurological SurveillanceMultiple SclerosisNCT01156298Biogen383
招募中
不适用
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström MacroglobulinemiaWaldenstrom MacroglobulinemiaNCT05640102BeiGene111
Unknown
不适用
Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical PracticeSmall Lymphocytic LymphomaChronic Lymphocytic LeukemiaNCT04094051The First Affiliated Hospital with Nanjing Medical University580
进行中(未招募)
不适用
A Prospective NIS to Evaluate the Clinical Outcomes of Risarg® (Ribociclib) Combined With Endocrine Therapy or Chemotherapy in Patients With HR+HER2 - aBC in Routine Clinical Practice in the RussiaHR+HER2- Advanced Breast CancerNCT06148506Novartis Pharmaceuticals376
